[LOGO]



                       N E W S   R E L E A S E


For Immediate Release

Contact:  HemaCare Corporation
          JoAnn Stover, Director of Investor Relations
          877.310.0717
          www.hemacare.com


  DEVERE JOINS HEMACARE AS NATIONAL DIRECTOR OF SALES AND MARKETING

- ---------------------------------------------------------------------

     Los  Angeles,  CA,  June  2,  2003 - HemaCare  Corporation  (OTC
Bulletin  Board: HEMA) announced today that Jody DeVere accepted  the
newly  created position of National Director of Sales and  Marketing.
DeVere  will  be  responsible for the Company's sales  and  marketing
strategy  including  product  and service  sales,  donor  recruitment
efforts, and therapeutic apheresis marketing.

     DeVere  brings to HemaCare more than 20 years of achievement  in
sales  and  marketing leadership positions across diverse industries.
DeVere most recently served as Director of Sales for RiverOne Inc., a
$40-million supply chain software provider.  Previously, she was Vice
President  of  Sales  and Marketing and founding  partner  of  Memory
Network Inc., a supplier of computer memory components.

     Judi  Irving, HemaCare's President and Chief Executive  Officer,
stated,  "We  are  pleased to welcome Ms. DeVere to  HemaCare.   Jody
brings  in-depth  sales management and marketing  experience  to  the
leadership  team;  this  knowledge is  essential  to  the  successful
execution of our business plan."

      "I am highly  energized  by the  challenge of helping HemaCare
achieve its goals," said DeVere.  "I believe there are many opportun-
ities to expand our customer base and  donor pool through innovative
sales and marketing initiatives."

                     About HemaCare Corporation

      Founded  in  1978,  HemaCare is a national  provider  of  blood
products and services and the only publicly traded company engaged in
the  blood services industry in the U.S.  HemaCare is licensed by the
FDA  and accredited by the American Association of Blood Banks.   The
company  focuses on providing cost effective, high quality  solutions
to the blood-related needs of U.S. hospitals.

                              - more -




This  press  release may contain "forward-looking statements"  within
the  meaning of the term in the Private Securities Litigation  Reform
Act  of  1995 (Section 27A of the Securities Act of 1933, as amended,
and  Section 21E of the Securities Exchange Act of 1934, as amended).
Additional written or oral forward-looking statements may be made  by
the  Company  from  time to time in filings with the  Securities  and
Exchange  Commission or otherwise.  Statements contained herein  that
are  not historical facts are forward-looking statements pursuant  to
the   safe   harbor  provisions  referenced  above.   Forward-looking
statements are inherently subject to risks and uncertainties some  of
which   cannot   be  predicted  or  quantified.    Such   risks   and
uncertainties   include,   without   limitation,   the   risks    and
uncertainties  set forth from time to time in reports  filed  by  the
Company  with  the Securities and Exchange Commission.  Although  the
Company  believes  that the expectations reflected in  such  forward-
looking statements are reasonable, it can give no assurance that such
expectations  will prove to be correct.  Consequently, future  events
and  actual results could differ materially from those set forth  in,
or  contemplated by, the forward-looking statements contained herein.
The Company undertakes no obligation to publicly release any revision
to  these  forward-looking  statements  made  to  reflect  events  or
circumstances after the date hereof.

                                 ###